{"id": "7750", "url": "https://fevir.net/resources/Group/7750", "date": "2022-01-11T17:20:56.687Z", "meta": {"versionId": "8", "lastUpdated": "2023-12-05T12:59:21.649Z"}, "name": "Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill", "type": "person", "status": "active", "contact": [{"telecom": [{"value": "support@computablepublishing.com", "system": "email"}]}], "quantity": 2244, "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "extension": [{"url": "http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact", "valueRelatedArtifact": {"type": "cite-as", "citation": "Participants in Anticoagulation for COVID-19 Combined (ATTACC, ACTIV-4a, and REMAP-CAP) RCT (hospitalized, not critically ill) [Group]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 7750. Revised 2022-01-11. Available at: https://fevir.net/resources/Group/7750. Computable resource at: https://fevir.net/resources/Group/7750."}}, {"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status", "valueCodeableConcept": {"coding": [{"code": "active", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type", "display": "Active"}]}}, {"url": "http://hl7.org/fhir/StructureDefinition/artifact-author", "valueContactDetail": {"name": "Brian S. Alper"}}], "publisher": "Computable Publishing LLC", "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "value": "7750", "system": "https://fevir.net/FOI", "assigner": {"display": "Computable Publishing LLC"}}], "membership": "enumerated", "description": "An enumerated group participating in a randomized trial.", "resourceType": "Group", "characteristic": [{"code": {"text": "Research Study for which this is the observed sample"}, "exclude": false, "description": "Participant in the Anticoagulation for COVID-19 Combined (ATTACC, ACTIV-4a, and REMAP-CAP) RCT", "valueReference": {"display": "Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 [Journal Article]. Contributors: The ATTACC, ACTIV-4a, and REMAP-CAP Investigators. In: The New England Journal of Medicine, DOI 10.1056/NEJMoa2105911. Published August 04, 2021. Available at: https://doi.org/10.1056/NEJMoa2105911.", "reference": "Citation/7636"}}, {"code": {"coding": [{"code": "305335007", "system": "http://snomed.info/sct", "display": "Admission to establishment (procedure)"}]}, "exclude": false, "description": "Hospitalized", "valueCodeableConcept": {"coding": [{"code": "32485007", "system": "http://snomed.info/sct", "display": "Hospital admission"}]}}, {"code": {"coding": [{"code": "64572001", "system": "http://snomed.info/sct", "display": "Disease (disorder)"}]}, "exclude": false, "description": "COVID-19", "valueCodeableConcept": {"text": "ATTACC and ACTIV-4a limited inclusion to patients with confirmed COVID-19 (and excluded initially entered participants who did not have confirmed SARS-CoV-2. REMAP-CAP however included patients with confirmed COVID-19 or suspected COVID-19 with intent to test for COVID-19.", "coding": [{"code": "840539006", "system": "http://snomed.info/sct", "display": "Disease caused by severe acute respiratory syndrome coronavirus 2 (disorder)"}]}}, {"code": {"coding": [{"code": "246112005", "system": "http://snomed.info/sct", "display": "Severity"}]}, "exclude": true, "description": "not critically ill", "valueCodeableConcept": {"text": "severe disease defined as ICU-level care or critically ill where ICU-level care was defined as the use of respiratory or cardiovascular organ support (oxygen delivered by high-flow nasal cannula, noninvasive or invasive mechanical ventilation, or the use of vasopressors or inotropes)", "coding": [{"code": "442452003", "system": "http://snomed.info/sct", "display": "Life threatening severity"}]}}], "combinationMethod": "all-of"}